Other Clinical Trial - ABC008 in Subjects With T-cell Large Granular

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02742727` - CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma	Phase 1/Phase 2
Completed	`NCT00076180` - Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia	Phase 1
Terminated	`NCT00278265` - Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia	Phase 2
Recruiting	`NCT05978141` - A Registry for People With T-cell Lymphoma

See also

Status

Clinical Trial

Phase

Recruiting

NCT02742727 - CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Phase 1/Phase 2

Completed

NCT00076180 - Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia

Phase 1

Terminated

NCT00278265 - Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia

Phase 2

Recruiting

NCT05978141 - A Registry for People With T-cell Lymphoma

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05532722
Study type	Interventional
Source	Abcuro, Inc.
Contact	Michael McClain
Phone	617-865-5078
Email	LGL-101_ClinicalTrial@abcuro.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	September 28, 2022
Completion date	December 2025

ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms